H e m a t o lo g y E d u c a t io n - European Hematology Association

More documents

Recommendations

Info

GlaxoSmithKline (Research Support; Consultant; Advisory Board); Roche (Research Support; Advisory Board); Celgene (Research Support; Consultant) Moreau P. Affiliations to disclose: Yes Janssen Cilag (Advisory Board); Millenium (Advisory Board); Celgene (Advisory Board) Mufti G. Affiliations to disclose: No Affiliations Narla M. Affiliations to disclose: No Affiliations Newland A. Affiliations to disclose: Yes Amgen (Research Support; Speakers Bureau; Advisory Board); Genentech (Research Support); GlaxoSmithKline (Research Support; Speakers Bureau; Advisory Board); Celgene (Advisory Board) Niemeyer C. Affiliations to disclose: No Affiliations Noizat-Pirenne F. Affiliations to disclose: No Affiliations Nowak-Göttl U. Affiliations to disclose: Unknown O'Donnell J. Affiliations to disclose: Yes Baxter (Research Support; Advisory Board); Bayer Schering Pharma (Research Support; Advisory Board); Octapharma (Speakers Bureau) Ottmann O. Affiliations to disclose: Yes Bristol Myers Squibb (Research Support; Advisory Board); Novartis (Research Support; Advisory Board; Speakers Bureau) Pabinger I. Affiliations to disclose: Yes Pfizer (Research Support; Speakers Bureau); Boeringer Ingelheim (Speakers Bureau; Advisory Board); Bayer Schering Pharma (Speakers Bureau; Advisory Board); Sanofi Aventis (Speakers Bureau); Amgen (Consultant); GlaxoSmithKline (Consultant); CSL Behring (Research Support) Pasqualucci L. Affiliations to disclose: No Affiliations Peake I. Affiliations to disclose: No Affiliations Piga A. Affiliations to disclose: Unknown Porkka K. Affiliations to disclose: Yes Novartis (Research Support; Consultant; Advisory Board); Bristol Myers Squibb (Research Support; Consultant; Advisory Board); Porter J. Affiliations to disclose: Yes Novartis (Research Support; Speakers Bureau; Advisory Board) Radford J. Affiliations to disclose: Yes Roche (Speakers Bureau; Advisory Board); GlaxoSmithKline (Stockholder; Advisory Board); Novartis (Speakers Bureau); Bayer Schering Pharma (Advisory Board); Mundipharma (Speakers Bureau; Advisory Board); AstraZeneca (Research Support; Advisory Board); Genmab (Advisory Board) Rezvani K. Affiliations to disclose: No Affiliations Ribatti D. Affiliations to disclose: No Affiliations Rice K. Affiliations to disclose: No Affiliations Ringden O. Affiliations to disclose: No Affiliations Rocha V. Affiliations to disclose: No Affiliations Rosendaal F. Affiliations to disclose: No Affiliations Rosenwald A. Affiliations to disclose: No Affiliations Rousselot P. Affiliations to disclose: Unknown Rowe J. Affiliations to disclose: No Affiliations Russell N. Affiliations to disclose: Unknown Saglio G. Affiliations to disclose: Yes Bristol Myers Squibb (Speakers Bureau; Advisory Board); Novartis (Research Support; Consultant; Advisory Board; Speakers Bureau); San Miguel J. Affiliations to disclose: Yes Millenium (Consultant; Speakers Bureau); Pharmion (Speakers Bureau); Janssen Cilag (Consultant; Speakers Bureau; Advisory Board); Celgene (Consultant; Advisory Board); Novartis (Advisory Board) Sanz M.A. Affiliations to disclose: No Affiliations Schlenk R. Affiliations to disclose: Yes Wyeth (Research Support); Pfizer (Research Support); Roche (Research Support); Celgene (Research Support); Amgen (Research Support); Chugai Sanofi-Aventis (Research Support) Schmitz N. Affiliations to disclose: Yes Roche (Research Support); Chugai Sanofi-Aventis (Research Support) Schnell P. Affiliations to disclose: No Affiliations Schrappe M. Affiliations to disclose: Yes Medac GmbH (Consultant) London, United Kingdom, June 9-12, 2011 Scott M.T. Affiliations to disclose: No Affiliations Hematology Education: the education programme for the annual congress of the European Hematology Association | 2011; 5(1) | 389 |
16 th Congress of the European Hematology Association Sloan S. Affiliations to disclose: Yes Immucor (Consultant) Smith O. Affiliations to disclose: No Affiliations Socié G. Affiliations to disclose: Yes Genzyme (Advisory Board); Therakos; Alexion (Research Support; Consultant) Sonneveld P. Affiliations to disclose: Yes Celgene (Advisory Board); Janssen Cilag (Advisory Board) Speleman F. Affiliations to disclose: No Affiliations Stamatopoulos K. Affiliations to disclose: No Affiliations Stasi R. Affiliations to disclose: Yes GlaxoSmithKline (Consultant; Speakers Bureau; Advisory Board); Amgen (Consultant; Speakers Bureau; Advisory Board); Nycomed (Advisory Board); Suppremol (Consultant); Novo Nordisk (Speakers Bureau) Storry J. Affiliations to disclose: Yes Grifols, SA (Advisory Board); Progenika Biopharma (Consultant) Sureda A. Affiliations to disclose: No Affiliations Tichelli A. Affiliations to disclose: No Affiliations Tournamille C. Affiliations to disclose: No Affiliations Urbano Ispizua A. Affiliations to disclose: No Affiliations Vacca A. Affiliations to disclose: No Affiliations van der Schoot E. Affiliations to disclose: Unknown Van Vlierberghe P. Affiliations to disclose: No Affiliations Vannucchi A.M. Affiliations to disclose: Yes Novartis (Advisory Board; Speaker); Shire Pharmaceuticals (Speaker) Verovskaya E. Affiliations to disclose: No Affiliations von Lindern M. Affiliations to disclose: Unknown Waage A. Affiliations to disclose: Yes Mundipharma (Speakers Bureau); Janssen Cilag (Speakers Bureau; Advisory Board); Celgene (Speakers Bureau) Ware R. Affiliations to disclose: No Affiliations Willman C. Affiliations to disclose: Unknown Wilson W. Affiliations to disclose: Yes Celgene (Advisory Board); Chugai Sanofi-Aventis (Advisory Board); Mundipharma (Advisory Board; Collaborations); Pharmacyclics (Advisory Board; Trial Collaborations); Genentech (Advisory Board); Millenium (Advisory Board; Trial Collaborations); Abbott (Clinical Trial Collaboration) | 390 | Hematology Education: the education programme for the annual congress of the European Hematology Association | 2011; 5(1)
Page 1 and 2:
H e m a t o l o g y E d u c a t i o
Page 3 and 4:
Copyright Information ©2011 by Eur
Page 5 and 6:
Editorial Board Education Book Edit
Page 7 and 8:
Acute lymphoblastic leukemia 1-8 Th
Page 10 and 11:
S. Schnell P. Van Vlierberghe A. Fe
Page 12 and 13:
lineage cells, and in differentiati
Page 14 and 15:
FLT3 mutations The FMS-like tyrosin
Page 16 and 17:
44. Bar-Eli M, Ahuja H, Foti A, Cli
Page 18 and 19:
J.M. Rowe 1,2 C. Ganzel 1 1 Shaare
Page 20 and 21:
treated on the MRC UKALL XII/ECOG29
Page 22 and 23:
asparaginase (PEG), where the Esche
Page 24 and 25:
or higher. It is, however, importan
Page 26 and 27:
25. Bruggemann M, Schrauder A, Raff
Page 28 and 29:
lymphoblastic leukemia: prospective
Page 30 and 31:
such as high white blood cell count
Page 32 and 33:
doxorubicine, there was a trend tow
Page 34 and 35:
of the aging process with respect t
Page 36 and 37:
K.L. Rice 1 M. Buzzai 2 J. Altman 1
Page 38 and 39:
ing FLT3-ITD, wild-type NPM1, or bo
Page 40 and 41:
ciated with gene activation, via th
Page 42 and 43:
leukemia with inv(16) and t(8;21):
Page 44 and 45:
99. Parsons DW, Jones S, Zhang X, e
Page 46 and 47:
abnormalities, some of which are al
Page 48 and 49:
file. 27,31 Thus, the double gene-m
Page 50 and 51:
karyotype represents a distinct gen
Page 52 and 53:
Table 1. Meta-analysis of 23 random
Page 54 and 55:
A recent study by the Center for In
Page 56 and 57:
Patients with HLA-matched related o
Page 58 and 59:
After allogeneic HSCT, an autologou
Page 60 and 61:
A. Bacigalupo Ospedale San Martino,
Page 62 and 63:
Table 2. The effect of HLA mismatch
Page 64 and 65:
References 1. Petersdorf EW, Malkki
Page 66 and 67:
neutrophil and platelet recovery an
Page 68 and 69:
Figure 2. One Year-Overall Survival
Page 70 and 71:
infused on day 21. No serious adver
Page 72 and 73:
W, et al. Effect of graft source on
Page 74 and 75:
TRM was higher for patients who rec
Page 76 and 77:
following a myeloablative preparati
Page 78 and 79:
effect. Surprisingly, none of the p
Page 80 and 81:
nancies. Bone Marrow Transplant. 20
Page 82 and 83:
J.G. Gilles Center for Molecular an
Page 84 and 85:
14C12 was humanized by grafting VH
Page 86 and 87:
Table 1. VWD Classification. VWD Su
Page 88 and 89:
Figure 1. Missense mutations found
Page 90 and 91:
associated with an increased bleedi
Page 92 and 93:
49. Brown SA, Eldridge A, Collins P
Page 94 and 95:
leed. These issues are especially i
Page 96 and 97:
estored function. 43,44 A phase I t
Page 98 and 99:
years’ experience of prophylactic
Page 100 and 101:
J.A. Burger Department of Leukemia,
Page 102 and 103:
chemotaxis, migration across vascul
Page 104 and 105:
Regulatory T cells (T reg), identif
Page 106 and 107:
16. Burger JA, Ghia P, Rosenwald A,
Page 108 and 109:
TE, Nowakowski GS, et al. CD49d exp
Page 110 and 111:
andomized trial demonstrating impro
Page 112 and 113:
Conclusions Chemoimmunotherapy has
Page 114 and 115:
with multiple comorbidities (≥ 2)
Page 116 and 117:
ment was finished in all 100 patien
Page 118 and 119:
Table 2. Treatment recommendation f
Page 120 and 121:
34. Ferrajoli A. The combination of
Page 122 and 123:
to be the source of additional gene
Page 124 and 125:
potential to prevent LSCs from acce
Page 126 and 127:
ABL1 confirms that eradication of d
Page 128 and 129:
65. Fiskus W, Pranpat M, Balasis M,
Page 130 and 131:
alive after 10 years. 11 Hence, CCy
Page 132 and 133:
each arm). A minimal change in myel
Page 134 and 135:
Any discussion about the definition
Page 136 and 137:
H. Kantarjian J. Cortes Leukemia De
Page 138 and 139:
59%; the CCyR rate was 44%. Among p
Page 140 and 141:
ern era of BCR-ABL1 tyrosine kinase
Page 142 and 143:
the hematopoietic system, 10 nor in
Page 144 and 145:
over the period of 6 weeks, demonst
Page 146 and 147:
Data on clonal changes in the blood
Page 148 and 149:
2006 Feb 1;107(3):924-30. 41. Liang
Page 150 and 151:
demonstrated that changes in osteob
Page 152 and 153:
“Mafia” transgenic mice in whic
Page 154 and 155:
68. Coetzee T, Fujita N, Dupree J,
Page 156 and 157:
ization. In WASP deficiency, lympho
Page 158 and 159:
Currently the epistatic relationshi
Page 160 and 161:
R. Küppers Institute of Cell Biolo
Page 162 and 163:
Figure 1. TNFAIP3 mutation in HL ce
Page 164 and 165:
Figure 2. HRS cells and their precu
Page 166 and 167:
Hansmann ML, et al. Detection of cl
Page 168 and 169:
fying patients for whom different a
Page 170 and 171:
prognosis HL, whilst those with res
Page 172 and 173:
12. Noordijk EM, Carde P, Dupouy N,
Page 174 and 175:
A. Sureda Consultant in Haematology
Page 176 and 177:
Figure 1. Long-term outcome of pati
Page 178 and 179:
from a MRD and 18 from MUDs. All pa
Page 180 and 181:
Parker PM, Stein AS, et al. High-do
Page 182 and 183:
R. Stasi Department of Haematology,
Page 184 and 185:
common variants in the regulatory r
Page 186 and 187:
against the TPO receptor (cMpl). 61
Page 188 and 189:
W.B. Mitchell A.A. Miller J.B. Buss
Page 190 and 191:
platelet counts and/or bleeding. Th
Page 192 and 193:
Mpl. Cell. 1994;77(7):1117-24. 6. d
Page 194 and 195:
ity and mortality associated with t
Page 196 and 197:
to azathioprine, and is particularl
Page 198 and 199:
stemming from antibodies against PE
Page 200 and 201:
L. Pasqualucci Institute for Cancer
Page 202 and 203:
cation of molecularly distinct subg
Page 204 and 205:
of cases) 46 and amplifications of
Page 206 and 207:
gene alterations in B cell lymphoma
Page 208 and 209:
W. Wilson National Cancer Institute
Page 210 and 211:
clear distinction among the lymphom
Page 212 and 213:
Treatment strategies in germinal ce
Page 214 and 215:
in ABC DLBCL (Hernandez et al., 201
Page 216 and 217:
DLBCL that mostly occurs in young p
Page 218 and 219:
phoma. J Clin Oncol. 2005;23:5347-5
Page 220 and 221:
Table 1. Diffuse Large B cell Lymph
Page 222 and 223:
sion/relapse are similar to those i
Page 224 and 225:
intensive therapy with curative int
Page 226 and 227:
A. Karsan Genome Sciences Centre an
Page 228 and 229:
Balanced translocations In contrast
Page 230 and 231:
some arm 5q have also been implicat
Page 232 and 233:
(H3K27) methyltransferase, and is a
Page 234 and 235:
38. Starczynowski DT, Morin R, McPh
Page 236 and 237:
G. Garcia-Manero Department of Leuk
Page 238 and 239:
trial evaluating different doses an
Page 240 and 241:
acid. 62 The second was a large mul
Page 242 and 243:
Borthakur G, et al. Cause of death
Page 244 and 245:
P. Krishnamurthy 1 G.J. Mufti 1,2 1
Page 246 and 247:
etween 1995 and 2005. 11 Five hundr
Page 248 and 249:
London, United Kingdom, June 9-12,
Page 250 and 251:
attainment of FDC post DLI. Interes
Page 252 and 253:
myelodysplastic syndromes is associ
Page 254 and 255:
ubiquitous chaperone that promotes
Page 256 and 257:
was thought that they are linked to
Page 258 and 259:
pathologic induction of miR-28 in M
Page 260 and 261:
STATs. Second, levels of HP1 alpha
Page 262 and 263:
72. Irandoust MI, Aarts LH, Roovers
Page 264 and 265:
A.M. Vannucchi Section of Hematolog
Page 266 and 267:
2,559 patients with a diagnosis of
Page 268 and 269:
tant use of aspirin should be caref
Page 270 and 271:
sions at this regard. Based on thes
Page 272 and 273:
in bcr-abl-negative myeloproliferat
Page 274 and 275:
Table 1. Prognostic scoring systems
Page 276 and 277:
Figure 1. Current inhibitors of JAK
Page 278 and 279:
Table 4. A risk-based approach to d
Page 280 and 281:
the flexibility to be adjusted as t
Page 282 and 283:
A. Vacca 1 D. Ribatti 2 1 Departmen
Page 284 and 285:
neovessel building together with MM
Page 286 and 287:
Mevastatin, a specific inhibitor of
Page 288 and 289:
egression of tumor vessels, and app
Page 290 and 291:
diagnosis does not require genetic
Page 292 and 293:
Genetics prognostic tools should be
Page 294 and 295:
sone induction improves outcome of
Page 296 and 297:
Table 1. Conventional chemotherapy
Page 298 and 299:
Novel agents given as consolidation
Page 300 and 301:
dence of peripheral neuropathy, gas
Page 302 and 303:
31. Barlogie B, Tricot G, Anaissie
Page 304 and 305:
Table 1. Major differences between
Page 306 and 307:
first line therapy have shown survi
Page 308 and 309:
transplantation, 7,91 and generally
Page 310 and 311:
methylation characterizes juvenile
Page 312 and 313:
Table 1. Clinical signs of possible
Page 314 and 315:
Table 4. Distribution of CSF involv
Page 316 and 317:
ently results in a less than 5% cum
Page 318 and 319:
90. German-Austrian-Swiss ALL-BFM S
Page 320 and 321:
U. Nowak-Göttl 1 R. Junker 1 A. Kr
Page 322 and 323:
Based on the data obtained from the
Page 324 and 325:
59. Male C, Chait P, Ginsberg JS, e
Page 326 and 327:
Table 1. Characteristic features of
Page 328 and 329:
Table 2. Mutational spectrum of CDA
Page 330 and 331:
megarakaryoblastic leukemia (AMKL)
Page 332 and 333:
R.E. Ware Professor and Vice-Chairm
Page 334 and 335:
protein, cytokines, and soluble adh
Page 336 and 337:
example, improving blood viscosity
Page 338 and 339:
92(9):1266-7. 36. Bensinger TA, Gil
Page 340 and 341:
London, United Kingdom, June 9-12,
Page 342 and 343:
port have also been used. 5 Combina
Page 344 and 345:
Wingard JR, Young J-AH, Boeckh MJ.
Page 346 and 347:
K. Rezvani 1 J. Barrett 2 1 Haemato
Page 348 and 349: include the childhood infectious il
Page 350 and 351: Summary Patients undergoing hematop
Page 352 and 353: Table 1. Key issues. In a retrospec
Page 354 and 355: invasive method to assess iron over
Page 356 and 357: stitution but even with optimal sub
Page 358 and 359: T.M. Hackeng Department of Biochemi
Page 360 and 361: and inhibits FVIIa, and that the se
Page 362 and 363: Figure 4. Regulation of coagulation
Page 364 and 365: T. Baglin Department of Haematology
Page 366 and 367: Figure 1. Illustration of alternati
Page 368 and 369: compared with 3.5% in patients with
Page 370 and 371: 49. Hron G, Kollars M, Binder BR, E
Page 372 and 373: Women receiving vitamin K antagonis
Page 374 and 375: molecular weight heparin as prophyl
Page 376 and 377: eral morbidity and mortality. 17-21
Page 378 and 379: the HOD construct. Furthermore, the
Page 380 and 381: Goals of future murine studies incl
Page 382 and 383: F. Noizat-Pirenne C. Tournamille Et
Page 384 and 385: phenotype. 26 In 2010, we investiga
Page 386 and 387: ody has been involved in DHTR. 37 T
Page 388 and 389: antigen. Cases can be encountered d
Page 390 and 391: S.R. Sloan Harvard Medical School &
Page 392 and 393: We also analyzed patient databases
Page 394 and 395: Index of authors Altman J. 27 Bacig
Page 396 and 397: Cornelissen J. Affiliations to disc
show all

H e m a t o lo g y E d u c a t io n - European Hematology Association

Create successful ePaper yourself

Delete template?

Save as template?